Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets innovative implantable visual prosthetics that enable blind individuals to achieve greater independence. The company’s lead product is the Argus® II Retinal Prosthesis System, which is currently being studied in a trial designed to test its safety and utility in individuals with dry age-related macular degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. For more information, visit the company’s website at www.secondsight.com.